The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing

British Journal of Clinical Pharmacology

Volumn 49, Issue 1, 2000, Pages 32-38

  Begg, Evan J ^a   Robson, Richard A ^a   Saunders, Darren A ^a   Graham, Garry G ^a,b   Buttimore, Rona C ^a   Neill, Alister M ^a   Town, G Ian ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Ciprofloxacin; Fleroxacin; Pharmacokinetics; Plasma; Sputum

Indexed keywords

CIPROFLOXACIN; FLEROXACIN;

ADULT; AGED; ANKLE EDEMA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BRONCHIECTASIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SPUTUM LEVEL; FEMALE; HEADACHE; HEARTBURN; HOT FLUSH; HUMAN; INDIGESTION; MALE; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; TENDINITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BRONCHIECTASIS; BRONCHITIS; CHRONIC DISEASE; CIPROFLOXACIN; FEMALE; FLEROXACIN; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SPUTUM; TIME FACTORS;

EID: 0033978199     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00105.x     Document Type: Article

References (17)

1. 1 Chin NX, Brittain DC, Neu HC. In vitro activity of RO 23-6240 a new fluorinated 4-quinolone. Antimicrob Agents Chemother 1986; 29: 675-680.
2. 2 Paganoni R, Herzog Ch, Braunsteiner A, Hohl P. Fleroxacin: in vitro activity worldwide against 20, 807 clinical isolates and comparison to ciprofloxacin and norfloxacin. J Antimicrob Chemother 1988; 22(Suppl D): 3-17.
3. 3 Georgopoulos A, Breyer S, Georgopoulos M, Mailer H, Graninger W. In vitro activity of fleroxacin. J Antimicrob Chemother 1988; 22(Suppl D): 25-29.
4. 4 Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434-461.
5. 5 Weidekamm E, Portmann R. Penetration of fleroxacin into body tissues and fluids. Am J Med 1993; 94(Supp1 3A): 75S-80S.
6. 6 Stuck AE, Kim DK, Frey FJ. Fleroxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 116-131.
7. 7 Chan CY, Lam AW, French GL. Rapid HPLC assay of fluoroquinolones in clinical specimens. J Antimicrob Chemother 1989; 23: 597-604.
8. 8 Myers CM, Blumer JL. High performance liquid chromatography of ciprofloxacin and its metabolites in serum, urine and sputum. J Chromatogr 1987; 422: 153-164.
9. 9 Heinzel G, Woloszczak R, Thomann P. Topfit 2 0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Gustav Fischer-Verlag, New York, 1993.
10. 10 Panneton A-C, Bergeron MG, LeBel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400-and 800-mg-dosage regimens. Antimicrob Agents Chemother 1988; 32: 1515-1520.
11. 11 Coburn WA. Simultaneous pharmacokinetic and pharmacodynamic modelling. J Pharmacokinet Biopharmaceut 1981; 9: 367-388.
12. 12 Noc DA, Kumor KM. Drug kinetics in low flux (small) anatomic compartments. J Pharm Sci 1983; 72: 718-719.
13. 13 Purves RD. Anomalous parameter estimates in the one-compartment model with first-order absorption. J Pharm Pharmacol 1993; 45: 934-936.
14. 14 Weidekamm E, Portmann R, Partos C, Bell D. Single and multiple dose pharmacokinetics of fleroxacin. J Antimicrob Chemother 1988; 22(Suppl D): 145-154.
15. 15 Baldwin DR, Wise R, Andrews JM, Gill M, Honeybourne D. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med 1993; 87: 595-601.
16. 16 Reid TMS, Gould IM, Colder D, et al. Brief report: Respiratory tract penetration of ciprofloxacin. Am J Med 1989; 87(Suppl 5A): 60S-61S.
17. 17 Schlenkoff D, Dalhoff A, Knopf J, Opferkuch W. Penetration of ciprofloxacin into human lung tissue following intravenous injection. Infection 1986; 14: 299-300.